Posted on 04/06/2009 in Pharmaceutical Company Product News Schering-Plough is pleased to have met an important milestone for Sycrest (asenapine), it has stated.
The drug has been designed to treat schizophrenia and manic episodes associated with bipolar I disorder and now the European Medicines Agency has accepted the marketing application of the sublingual tablets for review.
Results from a clinical investigation involving over 3,000 patients were submitted with the regulatory request.
During a meeting last November, the company highlighted asenapine as one of its five stars in its late-stage research and development programme, explained executive vice-president and president of the firm's research institute Dr Thomas P Koestler.
"At that time, we said that our aspirational filing date for asenapine in Europe was in 2009," he said.
Dr Koestler concluded he was satisfied this significant step had been reached within the first half of the year.
Meanwhile, Schering-Plough has launched an antifungal spray called Tinactin Chill to treat athlete's foot, which is a condition that is a common problem for young males aged between 14 and 22.Other news stories from 04/06/2009
Read more in the Zenopa News Archive
How this news is generated
|
